Sensorion S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALSEN.PA research report →
About the company
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss.
- CEO
- Amit D. Munshi
- IPO
- 2015
- Employees
- 63
- HQ
- Montpellier, FR
Price Chart
- Market Cap
- $73.75M
- P/E
- -2.46
- P/S
- 31.69
- P/B
- 1.63
- EV/EBITDA
- -1.54
- Div Yield
- 0.00%
- Gross Margin
- 69.83%
- Op Margin
- -1571.42%
- Net Margin
- -1264.68%
- ROE
- -58.01%
- ROIC
- -66.97%
- Revenue
- $0 · -100.00%
- Net Income
- $-29,429,000 · -13.31%
- EPS
- $-0.10 · -6.99%
- Op Income
- $-36,567,000
- FCF YoY
- -23.12%
- 52W High
- $0.81
- 52W Low
- $0.23
- 50D MA
- $0.37
- 200D MA
- $0.36
- Beta
- 0.38
- Avg Volume
- 2.20M
Get TickerSpark's AI analysis on ALSEN.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALSEN.PA coverage
Recent articles, reports, and earnings notes.
No research on ALSEN.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALSEN.PA report →Similar companies
Peers in the same neighborhood.